摘要
目的探讨腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的疗效及安全性。方法选择2011年3月~2014年12月本院收治的110例胃癌合并恶性腹水患者,随机分为观察组与对照组,每组55例,观察组采用腹腔灌注顺铂联合口服替吉奥胶囊治疗,对照组仅接受腹腔灌注顺铂治疗。连续治疗2个周期后进行疗效评价。结果观察组恶性腹水治疗效果显著优于对照组（P〈0.05）。观察组临床受益率显著高于对照组（P〈0.05）。观察组白细胞减少、贫血、恶心、呕吐等不良反应分级显著高于对照组（P〈0.05）。两组患者血小板减少、腹泻、黏膜炎、肝功能受损、肾功能受损等不良反应分级比较,差异无统计学意义（P〉0.05）。结论腹腔灌注顺铂联合口服替吉奥胶囊治疗胃癌合并恶性腹水具有疗效确切、不良反应可控等特点,值得临床推广应用。
Objective To investigate merit of gastric cancer patients with the efficacy and safety of cisplatin peritoneal perfusion with oral S-1 in the treat- malignant ascites. Methods 110 cases of gastric cancer with malignant ascites in our hospital from March 2011 to December 2014 were divided into observation group（55 cases） and control group（55 cas- es）,and observation group received cisplatin peritoneal perfusion with oral S-l,while control group was given cisplatin peritoneal perfusion.The efficacy and safety were evaluated after 2 courses of chemotherapy. Results The efficacy of malignant ascites in observation group was obvious better than that in control group （P〈0.05）,and the clinical benefit rate was obvious higher than that in control group （P〈O.O5）.The grades of neutropenia,anemia,nausea and vomiting in observation group was obvious higher than that in control group respectively（P〈0.05）,while there were no obvious differ- ences in the grades of thrombocytopenia,diarrhea,mucositis,impaired liver function,renal function damage between two groups（P〉0.05）. Conclusion The cisplatin peritoneal perfusion with oral S-1 in the treatment of gastric cancer patients with malignant ascites has good efficacy and controllable adverse reactions,which is worthy of being popularized and ap- plied.
出处
《中国当代医药》
2015年第26期49-51,共3页
China Modern Medicine
关键词
替吉奥
腹腔灌注
顺铂
胃癌
恶性腹水
S-1
Peritoneal perfusion
Cisplatin
Gastric cancer
Malignant ascites
